lifestyle.californiaconsumerbanking.com

Author: RenovoRx, Inc.

RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026

May 4, 2026
RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

May 4, 2026
RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment

May 4, 2026
RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement

May 3, 2026
RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

May 3, 2026
RenovoRx Announces $10 Million at Market Private Placement

May 2, 2026
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

April 29, 2026
RenovoRx Establishes RenovoCath® Medical Advisory Board

March 9, 2026
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

March 9, 2026
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting

March 8, 2026